Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | General Counsel and Secretary | May 16, 2022 | May 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date May 16, 2022 · Filed May 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68 · Expires 2032-05-15 | Direct | 2,301 |
Reported balance
After 2022-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-16 · Grant · Acquired 2,301 · Balance 2,301 F1: The option vests based on achievement of a performance objective. F2: 25% of the shares subject to the option shall vest on May 16, 2023, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68 · Expires 2032-05-15 | Direct | 3,752 |
Reported balance
After 2022-05-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-16 · Grant · Acquired 3,752 · Balance 3,752 F1: The option vests based on achievement of a performance objective. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68 · Expires 2032-05-15 | Direct | 361,586 |
Reported balance
After 2022-05-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-16 · Grant · Acquired 361,586 · Balance 361,586 F2: 25% of the shares subject to the option shall vest on May 16, 2023, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests based on achievement of a performance objective.
F2: 25% of the shares subject to the option shall vest on May 16, 2023, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 17, 2022 00:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 361,586 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001209191-22-029441 · doc4.xml · derivative · entry 3 Fawaz Ali D. · CIK 0001928287 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,586 Underlying: Common Stock · 361,586 shares Expires 2032-05-15 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest on May 16, 2023, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 16, 2022 Filed May 17, 2022 00:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 3,752 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001209191-22-029441 · doc4.xml · derivative · entry 2 Fawaz Ali D. · CIK 0001928287 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,752 Underlying: Common Stock · 3,752 shares Expires 2032-05-15 F1 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| May 16, 2022 Filed May 17, 2022 00:38 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 2,301 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001209191-22-029441 · doc4.xml · derivative · entry 1 Fawaz Ali D. · CIK 0001928287 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,301 Underlying: Common Stock · 2,301 shares Expires 2032-05-15 F1 · derivative.exercise_date: The option vests based on achievement of a performance objective. F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest on May 16, 2023, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.